Ceritinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 742 publications

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.

Journal: Future oncology (London, England)

Published: April 08, 2026

Inhibition of Four Anaplastic Lymphoma Kinase Inhibitors on the Activity of Human UDP-Glucuronosyltransferases and Prediction of Drug-Drug Interactions.

Inhibition of Four Anaplastic Lymphoma Kinase Inhibitors on the Activity of Human UDP-Glucuronosyltransferases and Prediction of Drug-Drug Interactions.

Journal: Chemical research in toxicology

Published: February 27, 2026

Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathway.

Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathway.

Journal: Translational oncology

Published: February 17, 2026

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.

Journal: Frontiers in oncology

Published: February 02, 2026

Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability.

Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability.

Journal: The Analyst

Published: November 13, 2025

Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models.

Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models.

Journal: Journal of medicinal chemistry

Published: November 10, 2025

Discovery of novel 2-azabicyclo[3.2.1]octane derivatives against non-small cell lung cancer from aconitine simplification.

Discovery of novel 2-azabicyclo[3.2.1]octane derivatives against non-small cell lung cancer from aconitine simplification.

Journal: Bioorganic chemistry

Published: October 30, 2025

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database.

Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database.

Journal: Science progress

Published: October 15, 2025

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response.

Journal: Haematologica

Published: September 23, 2025

Ceritinib-ibuprofen synergistic hepatotoxicity: Insights from real-world data and liver organoid models.

Ceritinib-ibuprofen synergistic hepatotoxicity: Insights from real-world data and liver organoid models.

Journal: Toxicology

Published: August 31, 2025

Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.

Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.

Journal: Journal of managed care & specialty pharmacy

Published: August 30, 2025

A Triple Threat Against Ovarian Cancer: Os(II)-Pt(IV)-Ceritinib Conjugates for Photodynamic Therapy, Chemotherapy, and Immunogenic Cell Death Induction.

A Triple Threat Against Ovarian Cancer: Os(II)-Pt(IV)-Ceritinib Conjugates for Photodynamic Therapy, Chemotherapy, and Immunogenic Cell Death Induction.

Journal: Angewandte Chemie (International ed. in English)

Published: August 25, 2025

Showing 1-12 of 742

Last Updated: 04/28/2026